Related Experiment Video

Updated: Mar 25, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

2.3K

Streptococcus pneumoniae Serotype Distribution and Pneumococcal Conjugate Vaccine Serotype Coverage among Pediatric

Stanley S Tai1

  • 1Department of Microbiology, College of Medicine, Howard University, Washington, DC 20059, USA. stai@howard.edu.

Vaccines
|February 25, 2016
PubMed

Insights

Pneumococcal conjugate vaccines (PCV7, PCV10, PCV13) protect against specific Streptococcus pneumoniae serotypes. This review analyzes pooled data to estimate vaccine coverage and track serotype distribution changes in Asian children.

Area of Science:

  • * Pediatric Infectious Diseases
  • * Vaccinology
  • * Epidemiology

Background:

  • * Pneumococcal infection remains a significant global health threat, particularly in young children.
  • * Capsular polysaccharide-based vaccines, including 7-valent (PCV7), 10-valent (PCV10), and 13-valent (PCV13) pneumococcal conjugate vaccines, are crucial for prevention.
  • * Current vaccines offer protection only against specific Streptococcus pneumoniae serotypes included in their formulations.

Purpose of the Study:

  • * To provide a precise estimation of serotype coverage for PCV7, PCV10, and PCV13 vaccines in East and Southeast Asia.
  • * To investigate shifts in Streptococcus pneumoniae serotype distribution among pediatric populations following the introduction of PCV7.
  • * To synthesize existing English literature data published between 2000 and 2014.

Main Methods:

  • * Systematic review and meta-analysis of published English literature.
  • * Inclusion of studies focusing on pediatric patients in East and Southeast Asia.
  • * Analysis of pooled data on Streptococcus pneumoniae serotype distribution and vaccine serotype coverage.

Main Results:

  • * Analysis of pooled data from East and Southeast Asia to determine serotype coverage for PCV7, PCV10, and PCV13.
  • * Examination of changes in Streptococcus pneumoniae serotype prevalence post-PCV7 implementation in pediatric populations.
  • * Identification of regional variations in serotype distribution and vaccine effectiveness.

Conclusions:

  • * The review aims to offer a comprehensive understanding of pneumococcal conjugate vaccine effectiveness in the target regions.
  • * Findings will inform public health strategies and vaccine policy for pneumococcal disease prevention in Asian children.
  • * Understanding serotype dynamics is essential for optimizing vaccination programs.

Keywords:
AsiaStreptococcus pneumoniaevaccine

More Related Videos

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination09:11

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination

Published on: September 25, 2014

22.7K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.8K

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
17
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
458
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
327
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
37